Merck & Co., Inc (NYSE:MRK) was the recipient of some unusual options trading on Wednesday. Investors bought 8,671 put options on the stock, AnalystRatings.NET reports. This represents an increase of 111% compared to the typical daily volume of 4,108 put options. Merck & Co., Inc. (NYSE:MRK) stock opened at $56.61 in last session, and closed at $55.79, while the day range of Merck & Co., Inc. (NYSE:MRK) stock is $55.72 – $56.79. The stock showed a positive weekly performance of -2.57%.
Bristol-Myers Squibb Co. (NYSE:BMY) announced that its new drug nivolumab plus Yervoy will move to a Phase III trial in non-small cell lung cancer (NSCLC) by year end. Bristol-Myers Squibb Co (NYSE:BMY) stock opened at $55.32 in last session, and closed at $54.18 by losing -1.92%. The 52 week range of $37.96 – $57.49. Company’s market capitalization is $89.40 billion.
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15th, to review first-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer and Louise Mehrotra, Vice President, Investor Relations, will host the call.
Johnson & Johnson (NYSE:JNJ) stock decreased -0.64% and finished the last session at $93.00. The EPS of the stock remained 4.81. Company’s market capitalization is $262.26 billion.
Zogenix, Inc. (NASDAQ:ZGNX) stock could be subject of harsh treatment in the market especially after going down by 22.7% on Wednesday trading session after its fierce rival Purdue Pharma announced it had completed the testing of an abuse resistant pain killer, Hydrocodone. Zogenix, Inc. (NASDAQ:ZGNX) stock opened the session at $3.46, and closed the session at $3.67. The 52 week range of the Zogenix, Inc. (NASDAQ:ZGNX) stock remained $1.25 – $5.19 and the day range was $3.42 – $3.72.